Previous close | 40.29 |
Open | 40.29 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 40.29 - 40.29 |
52-week range | 40.29 - 44.19 |
Volume | |
Avg. volume | 0 |
Market cap | 5.279B |
Beta (5Y monthly) | 0.50 |
PE ratio (TTM) | 27.60 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 1.66 (4.12%) |
Ex-dividend date | 24 Mar 2022 |
1y target est | N/A |
ORION CORPORATION PRESS RELEASE 8 August 2022 at 9:30 EEST U.S. FDA approves additional indication of darolutamide in combination with docetaxel for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC) Darolutamide now has indications in both non-metastatic castration-resistant prostate cancer (nmCRPC) for men at high risk of developing metastatic disease and metastatic hormone-sensitive prostate cancer (mHSPC).Approval under the FDA’s Real-Time Oncology Review (RTOR) pilot prog
ORION CORPORATION MANAGERS’ TRANSACTIONS 5 August 2022 at 11.15 EEST Orion Corporation: Managers’ transactions – Virve Laitinen Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons. Orion Oyj - Managers' Transactions____________________________________________Person subject to the notification requirementName: Virve
ORION CORPORATION HALF-YEAR FINANCIAL REPORT 1–6/2022 15 JULY 2022 at 12:00 EEST Orion Group Half-Year Financial Report 1–6/2022 This is a summary or Orion’s Half-Year Financial Report 1–6/2022. The complete report is attached to this stock exchange release and is available at https://www.orion.fi/en/Orion-group/investors/financial-reviews-and-presentations/ Net sales totalled EUR 554 million (EUR 524 million in 2021). Operating profit was EUR 153 (146) million.Profit before taxes was EUR 155 (1